TruScreen to Lodge a Pro Rata Renounceable Rights Issue

17 February 2023
NZX Limited
WELLINGTON
TruScreen to launch a pro-rata renounceable rights issue
TruScreen Group Limited (NZX/ASX:TRU) (TruScreen or TRU) is pleased to announce its intention to launch a one (1) for
five (5) pro-rata renounceable rights issue to raise up to circa NZD$2.2 million ("Rights Offer”).
An Offer Document will be issued by TruScreen and released to the market in due course. Shareholders should read the
Offer document in full before deciding what actions to take with their rights. Details of the Rights Offer are as follows:
Rights Offer size
and structure
~NZD$2.2 million pro rata renounceable rights offer to Eligible Shareholders
(defined below) at a ratio of 1 for 5 (Rights Offer). Approximately 72,573,250
new fully paid ordinary shares in TruScreen (New Shares) will be issued under
the Rights Offer.
Rights Offer price NZD$0.03/AUD$0.029 per New Share (Issue Price)
No Rights trading Rights will not be quoted on the NZX Main Board or the ASX. Holders of Rights
shall be entitled to sell their Rights privately off-market.
Eligibility Only TruScreen shareholders with registered addresses in New Zealand or
Australia on the Record Date will be entitled to participate in the Rights Offer
(Eligible Shareholders).
Oversubscriptions
and
Oversubscription
Bookbuild Facility
Eligible Shareholders who elect to take up all of their Rights in full will have an
opportunity to apply for additional shares, the issue price for which shall be
determined through an Oversubscription Bookbuild Facility process to be
undertaken by TRU. The final issue price to be paid under the Oversubscription
Bookbuild Facility process (Oversubscription Bookbuild Price) may ultimately
be greater than the Issue Price of NZD$0.03/AUD$0.029 per New Share, but in
no event will the Oversubscription Bookbuild Price be less than
NZD$0.03/AUD$0.029.
Eligible Shareholders and other eligible investors may be entitled to participate
in the Oversubscription Bookbuild Facility process via those
parties invited to
participate in the process by TRU.
Ordinary Shares The New Shares to be issued under the Rights Offer will rank equally in all
respects with the existing ordinary shares on issue in TRU.
T
he key dates for the Rights Offer are as follows:

Announcement of the Offer

17 February 2023
Record Date for determining Rights 5pm (NZDT)/3pm (AEDT) 27 February
2023

Opening Date for the Offer 28 February 2023

Dispatch of Offer Documents and Entitlement and
Acceptance Forms
28 February 2023
Closing Date for the Offer 5pm (NZDT)/3pm (AEDT) 15 March
2023

Closing Date for the Oversubscription Bookbuild Facility

16 March 2023

Announcement of results of the Offer and the
Oversubscription
Bookbuild Facility


17 March 2023
Allotment of New Shares, despatch of holder statements
and
commencement of trading of New Shares

22 March 2023

The above dates are subject to change at the discretion of TRU, subject to compliance with NZX and ASX Listing Rules
requirements. TRU reserves the right to withdraw the Rights Offer at any time prior to the issue of New Shares under
the Rights Offer at its absolute discretion.

A copy of the Corporate Action Notice and the Cleansing Notice accompany this announcement.

TruScreen Group Limited is being advised by CM Partners Limited.

Ends

Tony Ho
Chairman
Tel: +61 41 734 5839
Email: tonyho@truscreen.com

For investor relations queries please
visit www.truscreen.com or
contact:

Dr Beata Edling
Chief Executive Officer
beataedling@truscreen.com


Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com


Julia Maguire
Investor Relations
julia@thecapitalnetwork.com.au



About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand-based medical device company that
has developed an AI-enabled device that can detect precancerous and cancerous cervical changes
in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening
technologies that have only triage/adjunct functionality, the TruScreen device is registered as a
primary screening tool.
TruScreen’s cervical screening technology effectively resolves many of the ongoing issues with
conventional cytology, including failed samples, poor patient follow-up, patient discomfort, and the
need for supporting laboratory infrastructure.
The device is CE-marked, meaning it meets EU safety, health and environmental protection standards
required for sale and use throughout Europe. It is also National Medical Products Administration
approved for sale in China. In 2021, TruScreen established a manufacturing facility in China for
devices marketed and sold in China.
TruScreen is currently targeting product sales to a range of low and middle-income countries,
including China, Mexico, Vietnam, Russia, Zimbabwe and Saudi Arabia, where no large-scale cervical
cancer screening programmes and infrastructure are currently in place. By doing so, the Company
hopes to help improve the health and wellbeing of women worldwide.
To learn more, please visit: www.truscreen.com/